Please provide your email address to receive an email when new articles are posted on . The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2005 ASCO Annual Meeting. This abstract does not include a full text component.
Matched and Mismatched Allogeneic Stem-Cell Transplantation From Unrelated Donors Using Combined Graft-Versus-Host Disease Prophylaxis Including Rabbit Anti–T Lymphocyte Globulin Purpose: The primary ...
The speed and extent of biosimilar penetration differ across provider types. Provider awareness and incentives are significantly associated with biosimilar uptake. ABSTRACTObjectives: To identify ...
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...
Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings. Biosimilars ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results